Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Int J Cancer. 2014 Apr 15;134(8):1947-57. doi: 10.1002/ijc.28528. Epub 2013 Oct 24.
Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95% CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95% CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95% CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95% CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen.
前瞻性研究关于绝经前血清激素水平与乳腺癌风险的关系尚无定论,尤其是关于肿瘤亚型。我们使用嵌套在前瞻性欧洲癌症与营养前瞻性研究(EPIC)队列中的病例对照研究(801 例乳腺癌病例和 1132 例匹配对照),分析了诊断前血清雌二醇、游离雌二醇、孕酮、睾酮、游离睾酮和性激素结合球蛋白(SHBG)水平与雌激素和孕激素受体阳性和阴性乳腺癌肿瘤以及诊断时年龄的乳腺癌风险之间的关系。较高的诊断前血清睾酮和游离睾酮水平与乳腺癌总体风险增加相关[ORQ4-Q1=1.56(95%CI 1.15-2.13),ptrend=0.02 对于睾酮和 ORQ4-Q1=1.33(95%CI 0.99-1.79),ptrend=0.04 对于游离睾酮],但雌二醇、游离雌二醇、孕酮和 SHBG 没有观察到显著的风险关联。受体阳性和阴性肿瘤之间的异质性检验无显著差异。当按肿瘤诊断年龄分层分析时,观察到的雌二醇比值在诊断年龄小于 50 岁的乳腺癌中更强且接近显著[ORQ4-Q1=1.32(95%CI 0.87-2.01),ptrend=0.05],与诊断年龄为 50 岁或以上的乳腺癌相比[ORQ4-Q1=0.94(95%CI 0.60-1.47),ptrend=0.34,phet=0.04]。总之,我们的数据表明,绝经前循环睾酮水平较高与乳腺癌风险增加相关,但总体上未显示雌二醇或孕酮与乳腺癌风险之间存在显著关联,无论月经周期阶段或肿瘤受体状态如何,尽管观察到诊断年龄小于 50 岁的肿瘤中雌二醇水平升高可能会增加风险。